1xur › Citations

Making a new turn in matrix metalloprotease inhibition.

Wasserman ZR
Chem Biol 12 143-4 (2005)
Cited: 13 times
EuropePMC logo PMID: 15734640

Abstract

The paradigm for matrix metalloprotease inhibition combines active site tailoring and catalytic zinc ligation. But, selectivity has been difficult. Now, Engel et al. present novel compounds, completely selective for MMP-13, with a unique binding mode.

Articles - 1xur mentioned but not cited (3)

  1. Macrophage Migration Inhibitory Factor Acts as the Potential Target of a Newly Synthesized Compound, 1-(9'-methyl-3'-carbazole)-3, 4-dihydro-β-carboline. Ko PH, Shen YC, Murugan K, Huang CW, Sivakumar G, Pal P, Liao CC, Luo KS, Chuang EY, Tsai MH, Lai LC. Sci Rep 9 2147 (2019)
  2. Analysis of X-ray structures of matrix metalloproteinases via chaotic map clustering. Giangreco I, Nicolotti O, Carotti A, De Carlo F, Gargano G, Bellotti R. BMC Bioinformatics 11 500 (2010)
  3. Binary image representation of a ligand binding site: its application to efficient sampling of a conformational ensemble. Sung E, Kim S, Shin W. BMC Bioinformatics 11 256 (2010)


Reviews citing this publication (1)

  1. Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects. Zhang C, Kim SK. Mar Drugs 7 71-84 (2009)

Articles citing this publication (9)

  1. Recent advances in MMP inhibitor design. Fisher JF, Mobashery S. Cancer Metastasis Rev 25 115-136 (2006)
  2. Modeling Structural Coordination and Ligand Binding in Zinc Proteins with a Polarizable Potential. Zhang J, Yang W, Piquemal JP, Ren P. J Chem Theory Comput 8 1314-1324 (2012)
  3. Zinc deficiency impairs wound healing of colon anastomosis in rats. Binnebösel M, Grommes J, Koenen B, Junge K, Klink CD, Stumpf M, Ottinger AP, Schumpelick V, Klinge U, Krones CJ. Int J Colorectal Dis 25 251-257 (2010)
  4. Allosteric inhibition of the neuropeptidase neurolysin. Hines CS, Ray K, Schmidt JJ, Xiong F, Feenstra RW, Pras-Raves M, de Moes JP, Lange JH, Melikishvili M, Fried MG, Mortenson P, Charlton M, Patel Y, Courtney SM, Kruse CG, Rodgers DW. J Biol Chem 289 35605-35619 (2014)
  5. A Cycloaddition Strategy for Use toward Berkelic Acid, an MMP Inhibitor and Potent Anticancer Agent Displaying a Unique Chroman Spiroketal Motif. Huang Y, Pettus TR. Synlett 9 1353-1356 (2008)
  6. Cryo-EM structure of a catalytic amyloid fibril. Heerde T, Bansal A, Schmidt M, Fändrich M. Sci Rep 13 4070 (2023)
  7. MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides. Fobian YM, Freskos JN, Barta TE, Bedell LJ, Heintz R, Kassab DJ, Kiefer JR, Mischke BV, Molyneaux JM, Mullins P, Munie GE, Becker DP. Bioorg Med Chem Lett 21 2823-2825 (2011)
  8. A combined molecular modeling study on gelatinases and their potent inhibitors. Xi L, Du J, Li S, Li J, Liu H, Yao X. J Comput Chem 31 24-42 (2010)
  9. Repurposing de novo designed entities reveals phosphodiesterase 3B and cathepsin L modulators. Rodrigues T, Lin YC, Hartenfeller M, Renner S, Lim YF, Schneider G. Chem Commun (Camb) 51 7478-7481 (2015)


Quick links